251 related articles for article (PubMed ID: 28580506)
1. Prolonged Overall Treatment Time and Lack of Skin Rash Negatively Impact Overall Survival in Locally Advanced Head and Neck Cancer Patients Treated with Radiotherapy and Concomitant Cetuximab.
Roman J; Dissaux G; Gouillou M; Gobel Y; Potard G; Leclere JC; Conan-Charlet V; Gujral D; Abgral R; Guibourg B; Pradier O; Schick U
Target Oncol; 2017 Aug; 12(4):505-512. PubMed ID: 28580506
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
3. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Mizumachi T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H; Homma A
Int J Clin Oncol; 2019 May; 24(5):468-475. PubMed ID: 30656463
[TBL] [Abstract][Full Text] [Related]
5. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.
Bar-Ad V; Zhang QE; Harari PM; Axelrod R; Rosenthal DI; Trotti A; Jones CU; Garden AS; Song G; Foote RL; Raben D; Shenouda G; Spencer SA; Harris J; Le QT
Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1346-1354. PubMed ID: 27212198
[TBL] [Abstract][Full Text] [Related]
6. Individualized treatment of head neck squamous cell carcinoma patients aged 70 or older with radiotherapy alone or associated to cisplatin or cetuximab: impact of weekly radiation dose on loco-regional control.
Belgioia L; Bacigalupo A; Missale F; Vecchio S; Chiola I; Callegari S; Verzanini E; Peretti G; Corvò R
Med Oncol; 2019 Mar; 36(5):42. PubMed ID: 30927146
[TBL] [Abstract][Full Text] [Related]
7. Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer.
Levy A; De Felice F; Bellefqih S; Guigay J; Deutsch E; Nguyen F; Blanchard P; Tao Y
Head Neck; 2016 Apr; 38 Suppl 1():E905-10. PubMed ID: 25974356
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck.
Göksu SS; Tatlı AM; Geredeli Ç; Atcı M; Besen AA; Mertsoylu H; Uysal M; Özdoğan M; Aydın SG; Bilici A; Karaağaç M; Artaç M; Kaplan MA; Ebinç S; Coşkun HŞ
Cancer Chemother Pharmacol; 2021 Nov; 88(5):805-812. PubMed ID: 34312705
[TBL] [Abstract][Full Text] [Related]
9. Impact of prophylactic percutaneous endoscopic gastrostomy tube placement on treatment tolerance in head and neck cancer patients treated with cetuximab plus radiation.
Yamazaki T; Enokida T; Wakasugi T; Zenda S; Motegi A; Arahira S; Akimoto T; Tahara M
Jpn J Clin Oncol; 2016 Sep; 46(9):825-31. PubMed ID: 27317736
[TBL] [Abstract][Full Text] [Related]
10. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review.
Bonomo P; Loi M; Desideri I; Olmetto E; Delli Paoli C; Terziani F; Greto D; Mangoni M; Scoccianti S; Simontacchi G; Francolini G; Meattini I; Caini S; Livi L
Crit Rev Oncol Hematol; 2017 Dec; 120():98-110. PubMed ID: 29198343
[TBL] [Abstract][Full Text] [Related]
11. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
[TBL] [Abstract][Full Text] [Related]
12. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.
Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T
Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692
[TBL] [Abstract][Full Text] [Related]
13. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Tao Y; Biau J; Sun XS; Sire C; Martin L; Alfonsi M; Prevost JB; Modesto A; Lafond C; Tourani JM; Miroir J; Kaminsky MC; Coutte A; Liem X; Chautard E; Vauleon E; Drouet F; Ruffier A; Ramee JF; Waksi G; Péchery A; Wanneveich M; Guigay J; Aupérin A; Bourhis J
Ann Oncol; 2023 Jan; 34(1):101-110. PubMed ID: 36522816
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study.
Addeo R; Caraglia M; Vincenzi B; Luce A; Montella L; Mastella A; Mazzone S; Ricciardiello F; Carraturo M; Del Prete S; Sperlongano P
Chemotherapy; 2019; 64(1):48-56. PubMed ID: 31242489
[TBL] [Abstract][Full Text] [Related]
19. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice?
Agarwal JP; Gupta T; Kalyani N; Budrukkar A; Laskar SG; Murthy V; Kumar P; Narohna V; Pai P; Chaturvedi P; D'cruz AK
Indian J Cancer; 2011; 48(2):148-53. PubMed ID: 21768657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
